Pre-made Evolocumab benchmark antibody ( Whole mAb, anti-PCSK9 therapeutic antibody, Anti-FH3/FHCL3/HCHOLA3/LDLCQ1/NARC-1/NARC1/PC9 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Evolocumab biosimilar, Whole mAb, Anti-PCSK9 Antibody: Anti-FH3/FHCL3/HCHOLA3/LDLCQ1/NARC-1/NARC1/PC9 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Evolocumab (trade name Repatha) is a monoclonal antibody medication designed for the treatment of hyperlipidemia.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	List Price(In USD)	Discount off	Discount Price
GMP-Bios-ab-202-1mg	1mg	3090	Inquiry	Inquiry

Size： 1mg | 10mg | 100mg

Description

Products Name (INN Index)	Pre-Made Evolocumab biosimilar, Whole mAb, Anti-PCSK9 Antibody: Anti-FH3/FHCL3/HCHOLA3/LDLCQ1/NARC-1/NARC1/PC9 therapeutic antibody
INN Name	Evolocumab
Target	PCSK9
Format	Whole mAb
Derivation	Human
Species Reactivity	Human
CH1 Isotype	IgG2
VD LC	Lambda
Highest_Clin_Trial (Jan '20)	Approved
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2012
Year Recommended	2013
Companies	Amgen;Amgen Astellas BioPharma;University Hospital Inselspital
Conditions Approved	Coronary disorders;Hypercholesterolaemia;Hyperlipoproteinaemia type IIa;Myocardial infarction;Stroke
Conditions Active	Hyperlipidaemia;Coronary artery disease;Dyslipidaemias
Conditions Discontinued	na
Development Tech	Abgenix XenoMouse